Clinical Pharmacokinetics

, Volume 49, Issue 2, pp 71–87

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

  • Michael J. Hanley
  • Darrell R. Abernethy
  • David J. Greenblatt
Review Article

Abstract

The prevalence of obesity has dramatically increased in recent years and now includes a significant proportion of the world’s children, adolescents and adults. Obesity is linked to a number of co-morbidities, the most prominent being type 2 diabetes mellitus. While many agents are available to treat these conditions, the current knowledge regarding their disposition in the obese remains limited.

Over the years, both direct and indirect methodologies have been utilized to assess body composition. Commonly used direct measures include underwater weighing, skinfold measurement, bioelectrical impedance analysis and dual-energy x-ray absorptiometry. Unfortunately, these methods are not readily available to the majority of clinicians. As a result, a number of indirect measures to assess body composition have been developed. Indirect measures rely on patient attributes such as height, bodyweight and sex. These size metrics are often utilized clinically and include body mass index (BMI), body surface area (BSA), ideal bodyweight (IBW), percent IBW, adjusted bodyweight, lean bodyweight (LBW) and predicted normal weight (PNWT).

An understanding of how the volume of distribution (Vd) of a drug changes in the obese is critical, as this parameter determines loading-dose selection. The Vd of a drug is dependent upon its physiochemical properties, the degree of plasma protein binding and tissue blood flow. Obesity does not appear to have an impact on drug binding to albumin; however, data regarding α1-acid glycoprotein binding have been contradictory. A reduction in tissue blood flow and alterations in cardiac structure and function have been noted in obese individuals. At the present time, a universal size descriptor to describe the Vd of all drugs in obese and lean individuals does not exist.

Drug clearance (CL) is the primary determinant to consider when designing a maintenance dose regimen. CL is largely controlled by hepatic and renal physiology. In the obese, increases in cytochrome P450 2E1 activity and phase II conjugation activity have been observed. The effects of obesity on renal tubular secretion, tubular reabsorption, and glomerular filtration have not been fully elucidated. As with the Vd, a single, well validated size metric to characterize drug CL in the obese does not currently exist. Therefore, clinicians should apply a weight-normalized maintenance dose, using a size descriptor that corrects for differences in absolute CL between obese and non-obese individuals.

The elimination half-life (t½) of a drug depends on both the Vd and CL. Since the Vd and CL are biologically independent entities, changes in the t½ of a drug in obese individuals can reflect changes in the Vd, the CL, or both.

This review also examines recent publications that investigated the disposition of several classes of drugs in the obese — antibacterials, anticoagulants, antidiabetics, anticancer agents and neuromuscular blockers.

In conclusion, pharmacokinetic data in obese patients do not exist for the majority of drugs. In situations where such information is available, clinicians should design treatment regimens that account for any significant differences in the CL and Vd in the obese.

References

  1. 1.
    Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008; 32: 1431–37CrossRefGoogle Scholar
  2. 2.
    Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006; 12: 62–6PubMedCrossRefGoogle Scholar
  3. 3.
    World Health Organization. Obesity and overweight [fact sheet no. 311; online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs311/en/index.html [Accessed 2009 Sep 29]
  4. 4.
    Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev 2004; 5 Suppl. 1: 4–85PubMedCrossRefGoogle Scholar
  5. 5.
    World Health Organization. Information sheet on obesity and overweight [online]. Available from URL: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ [Accessed 2009 Sep 29]
  6. 6.
    Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197–209PubMedCrossRefGoogle Scholar
  7. 7.
    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med 2007; 356: 213–5PubMedCrossRefGoogle Scholar
  8. 8.
    Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet 1986; 11: 199–213PubMedCrossRefGoogle Scholar
  9. 9.
    Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1–7PubMedCrossRefGoogle Scholar
  10. 10.
    Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215–31PubMedCrossRefGoogle Scholar
  11. 11.
    Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1982; 7: 108–24PubMedCrossRefGoogle Scholar
  12. 12.
    Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 1993; 25: 103–14PubMedCrossRefGoogle Scholar
  13. 13.
    Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415–26PubMedCrossRefGoogle Scholar
  14. 14.
    Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119–33PubMedCrossRefGoogle Scholar
  15. 15.
    Ellis KJ. Human body composition: in vivo methods. Physiol Rev 2000; 80: 649–80PubMedGoogle Scholar
  16. 16.
    Fields DA, Goran MI, McCrory MA. Body-composition assessment via airdisplacement plethysmography in adults and children: a review. Am J Clin Nutr 2002; 75: 453–67PubMedGoogle Scholar
  17. 17.
    Gray DS, Bray GA, Bauer M, et al. Skinfold thickness measurements in obese subjects. Am J Clin Nutr 1990; 51: 571–7PubMedGoogle Scholar
  18. 18.
    Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis: part I. Review of principles and methods. Clin Nutr 2004; 23: 1226–43PubMedCrossRefGoogle Scholar
  19. 19.
    Sutcliffe JF. A review of in vivo experimental methods to determine the composition of the human body. Phys Med Biol 1996; 41: 791–833PubMedCrossRefGoogle Scholar
  20. 20.
    Pietrobelli A, Formica C, Wang Z, et al. Dual-energy x-ray absorptiometry body composition model: review of physical concepts. Am J Physiol 1996; 271: E941–51PubMedGoogle Scholar
  21. 21.
    World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation [WHO technical report no. 894; online]. Available from URL: http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf [Accessed 2009 Sep 29]
  22. 22.
    Du Bois D, Du Bois EF. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863CrossRefGoogle Scholar
  23. 23.
    Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098PubMedGoogle Scholar
  24. 24.
    Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4: 108–13PubMedCrossRefGoogle Scholar
  25. 25.
    Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650–5Google Scholar
  26. 26.
    Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean body weight. Clin Pharmacokinet 2005; 44: 1051–65PubMedCrossRefGoogle Scholar
  27. 27.
    Green B, Duffull SB. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743–4PubMedCrossRefGoogle Scholar
  28. 28.
    Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505–8PubMedCrossRefGoogle Scholar
  29. 29.
    Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43: 1167–78PubMedCrossRefGoogle Scholar
  30. 30.
    Rivlin RS. Keeping the young-elderly healthy: is it too late to improve our health through nutrition? Am J Clin Nutr 2007; 86: 1572–6SGoogle Scholar
  31. 31.
    Han PY, Duffull SB, Kirkpatrick CMJ, et al. Response to “influence of lean body weight on anticancer drug clearance” [letter]. Clin Pharmacol Ther 2009; 85: 24CrossRefGoogle Scholar
  32. 32.
    Niazi S. Volume of distribution as a function of time. J Pharm Sci 1976; 65: 452–4PubMedCrossRefGoogle Scholar
  33. 33.
    Greenblatt DJ, Abernethy DR, Divoll M. Is volume of distribution at steady state a meaningful kinetic variable. J Clin Pharmacol 1983; 23: 391–400PubMedGoogle Scholar
  34. 34.
    Hollenstein UM, Brunner M, Schmid R, et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight adjusted dosing. Int J Obes Relat Metab Disord 2001; 25: 354–8PubMedCrossRefGoogle Scholar
  35. 35.
    Jansson PA, Larsson A, Lönnroth PN. Relationship between blood pressure, metabolic variables, and blood flow in obese subjects with or without noninsulin-dependent diabetes mellitus. Eur J Clin Invest 1998; 28: 813–8PubMedCrossRefGoogle Scholar
  36. 36.
    Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci 1996; 91: 679–83PubMedGoogle Scholar
  37. 37.
    Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008; 88: 389–419PubMedCrossRefGoogle Scholar
  38. 38.
    Abernethy DR, Greenblatt DJ, Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984; 9: 177–83PubMedCrossRefGoogle Scholar
  39. 39.
    Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 1985; 42: 468–71PubMedCrossRefGoogle Scholar
  40. 40.
    Benedek IH, Fiske III WD, Griffen WO. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 1983; 16: 751–4PubMedCrossRefGoogle Scholar
  41. 41.
    Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984; 18: 941–6PubMedCrossRefGoogle Scholar
  42. 42.
    Cheymol G. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 1987; 27: 874–9PubMedGoogle Scholar
  43. 43.
    Derry CL, Kroboth PD, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal weight men. J Clin Psychopharmacol 1995; 15: 197–205PubMedCrossRefGoogle Scholar
  44. 44.
    Saadeh S. Nonalcoholic fatty liver disease and obesity. Nutr Clin Pract 2007; 22: 1–10PubMedCrossRefGoogle Scholar
  45. 45.
    Ijaz S, Yang W, Winslet MC, et al. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447–56PubMedGoogle Scholar
  46. 46.
    O’shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359–67PubMedCrossRefGoogle Scholar
  47. 47.
    Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428–35PubMedCrossRefGoogle Scholar
  48. 48.
    Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucoronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983; 101: 873–80PubMedGoogle Scholar
  49. 49.
    Abernethy DR, Divoll M, Greenblatt DJ, et al. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 1982; 31: 783–90PubMedCrossRefGoogle Scholar
  50. 50.
    Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51: 2741–7PubMedCrossRefGoogle Scholar
  51. 51.
    Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 2009; 85: 23–4PubMedCrossRefGoogle Scholar
  52. 52.
    Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol 1983; 23: 369–76PubMedGoogle Scholar
  53. 53.
    Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci 1982; 71: 942–4PubMedCrossRefGoogle Scholar
  54. 54.
    Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45: 48–56PubMedCrossRefGoogle Scholar
  55. 55.
    Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245–9PubMedCrossRefGoogle Scholar
  56. 56.
    Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52: 405–11PubMedCrossRefGoogle Scholar
  57. 57.
    Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45: 845–51PubMedCrossRefGoogle Scholar
  58. 58.
    Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63–8PubMedCrossRefGoogle Scholar
  59. 59.
    Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006; 50: 1222–7PubMedCrossRefGoogle Scholar
  60. 60.
    Allard S, Kinzig M, Boivin G, et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54: 368–73PubMedCrossRefGoogle Scholar
  61. 61.
    Newman D, Scheetz MH, Adeyemi OA, et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007; 41: 1734–39PubMedCrossRefGoogle Scholar
  62. 62.
    Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427–32PubMedCrossRefGoogle Scholar
  63. 63.
    Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 2005; 62: 464–7PubMedGoogle Scholar
  64. 64.
    MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl. 2: ii17–25PubMedGoogle Scholar
  65. 65.
    Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HC1, phenylpropanolamine HC1, and dextromethorpan HBr. J Clin Pharmacol 2001; 41: 563–72PubMedCrossRefGoogle Scholar
  66. 66.
    Burkhardt O, Borner K, von der Höh N, et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002; 50: 707–12PubMedCrossRefGoogle Scholar
  67. 67.
    Rice L, Hursting MJ, Baillie GM. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007; 47: 1028–34PubMedCrossRefGoogle Scholar
  68. 68.
    Weitz JI. Low-molecular-weight heparin. N Engl J Med 1997; 337: 688–98PubMedCrossRefGoogle Scholar
  69. 69.
    Sanderink GJ, Liboux AL, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72: 308–18PubMedCrossRefGoogle Scholar
  70. 70.
    Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87: 817–23PubMedGoogle Scholar
  71. 71.
    Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005; 116: 41–50PubMedCrossRefGoogle Scholar
  72. 72.
    Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56: 96–103PubMedCrossRefGoogle Scholar
  73. 73.
    Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics: a preliminary study. Eur J Clin Pharmacol 2000; 56: 293–7PubMedCrossRefGoogle Scholar
  74. 74.
    Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004; 38: 30–5PubMedCrossRefGoogle Scholar
  75. 75.
    Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876–86PubMedCrossRefGoogle Scholar
  76. 76.
    Herman GA, Stevens CS, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675–88PubMedCrossRefGoogle Scholar
  77. 77.
    Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55–72PubMedCrossRefGoogle Scholar
  78. 78.
    Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25: 4707–13PubMedCrossRefGoogle Scholar
  79. 79.
    Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93: 4436–40PubMedGoogle Scholar
  80. 80.
    Nguyen L, Leger F, Lennon S, et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006; 57: 191–8PubMedCrossRefGoogle Scholar
  81. 81.
    Ritzmo C, Söderhäll S, Karlén J, et al. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient. Pediatr Hematol Oncol 2007; 24: 437–45PubMedCrossRefGoogle Scholar
  82. 82.
    Palm C, Björk O, Björkholm M, et al. Quantification of doxorubicin in plasma: a comparative study of capillary and venous blood sampling. Anticancer Drugs 2001; 12: 859–64PubMedCrossRefGoogle Scholar
  83. 83.
    Eksborg S, Palm C, Björk O. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs 2000; 11: 129–36PubMedCrossRefGoogle Scholar
  84. 84.
    Eksborg S, Söderhäll S, Frostvik-Stolt M, et al. Plasma pharmacokinetics of etoposide (VP-16) after IV administration to children. Anticancer Drugs 2000; 11: 237–41PubMedCrossRefGoogle Scholar
  85. 85.
    de Jonge ME, Mathôt RA, van Dam SM, et al. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa, and carboplatin. Cancer Chemother Pharmacol 2002; 50: 251–5PubMedCrossRefGoogle Scholar
  86. 86.
    Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14: 3000–8PubMedGoogle Scholar
  87. 87.
    Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99: 1090–4PubMedCrossRefGoogle Scholar
  88. 88.
    Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99: 1086–9PubMedCrossRefGoogle Scholar
  89. 89.
    Pühringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16: 507–10PubMedGoogle Scholar
  90. 90.
    Loveland SM, Lewin JJ III, Amabile CM, et al. Obese man treated with drotrecogin alfa (activated). Ann Pharmacother 2003; 37: 918–9PubMedCrossRefGoogle Scholar
  91. 91.
    Small DS, Levy H. Comment: obese man treated with drotrecogin alfa (activated). Ann Pharmacother 2004; 38: 722PubMedCrossRefGoogle Scholar
  92. 92.
    Levy H, Small D, Heiselman DE, et al. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Ann Pharmacother 2005; 39: 262–7PubMedCrossRefGoogle Scholar
  93. 93.
    Wójcicki J, Jaroszynska M, Droździk M, et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos 2003; 24: 211–8PubMedCrossRefGoogle Scholar
  94. 94.
    Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997; 43: 563–70PubMedCrossRefGoogle Scholar
  95. 95.
    Viriyayudhakorn S, Thitiarchakul S, Nachaisit S, et al. Pharmacokinetics of quinine in obesity. Trans R Soc Trop Med Hyg 2000; 94: 425–8PubMedCrossRefGoogle Scholar
  96. 96.
    Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003; 44: 540–9PubMedCrossRefGoogle Scholar
  97. 97.
    Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002; 99(5 Pt 1): 820–7PubMedCrossRefGoogle Scholar
  98. 98.
    Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46–52PubMedCrossRefGoogle Scholar
  99. 99.
    Brunner Huber LR, Hogue CJ, Stein AD, et al. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 2006; 16: 637–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Michael J. Hanley
    • 1
  • Darrell R. Abernethy
    • 2
  • David J. Greenblatt
    • 1
  1. 1.Department of Pharmacology and Experimental TherapeuticsTufts University School of Medicine and Tufts Medical CenterBostonUSA
  2. 2.United States PharmacopeiaRockvilleUSA

Personalised recommendations